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Abstract
Background: Botulinum Toxin Type-A (BoNT/A) intraprostatic injection can induce prostatic
involution and improve LUTS and urinary flow in patients with Benign Prostatic Enlargement (BPE).
However, the duration of these effects is unknown. The objective of this work was to determine
the duration of prostate volume reduction after one single intraprostatic injection of 200U of
Botulinum Toxin Type-A.
Methods: This is an extension of a 6 month study in which 21 frail elderly patients with refractory
urinary retention and unfit for surgery were submitted to intraprostatic injection of BoNT/A-200U,
by ultrasound guided transrectal approach. In spite of frail conditions, eleven patients could be
followed during 18 months. Prostate volume, total serum PSA, maximal flow rate (Qmax), residual
volume (PVR) and IPSS-QoL scores were determined at 1, 3, 6, 12 and 18 months post-treatment.
Results: Mean prostate volume at baseline, 82 ± 16 ml progressively decreased from month one
coming to 49 ± 9,5 ml (p = 0,003) at month six. From this moment on, prostate volume slowly
recovered, becoming identical to baseline at 18 months (73 ± 16 ml, p = 0.03). Albeit non
significant, serum PSA showed a 25% decrease from baseline to month 6. The 11 patients resumed
spontaneous voiding at month one. Mean Qmax was 11,3 ± 1,7 ml/sec and remained unchanged
during the follow-up period. PVR ranged from 55 ± 17 to 82 ± 20 ml and IPSS score from10 to 12
points.
Conclusion: Intraprostatic BoNT/A injection is safe and can reduce prostate volume for a period
of 18 months. During this time a marked symptomatic improvement can be maintained.
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Background
Botulinum Toxin type A (BoNT/A), the strongest biologi-
cal neurotoxin known to man, recently has been investi-
gated as a treatment for multiple disorders, including
lower urinary tract dysfunction [1].
BoNT/A investigation for the treatment of benign pros-
tatic enlargement (BPE) due to benign prostatic hyperpla-
sia (BPH) started in 2003 [2] after the experimental
demonstration that intraprostatic injection of the neuro-
toxin induced prostatic atrophy in the Rat [3]. In an
exploratory study, which involved injection of 200 U of
BoNT/A (Botox) in moderate to large prostate glands, a
rapid prostate volume decrease was induced and still
p r e s e n t  a t  1 2  m o n t h s  [ 2 ] .  F o l l o w i n g  t h i s  s t u d y ,  o t h e r
groups reported similar findings when injecting prostate
glands of 50 ml or larger [4-7]. BoNT/A injection in
smaller prostate glands caused a much lesser reduction in
prostate volume but a 15% reduction was still observed
[8-10]. Independently of the extent of prostate volume
reduction, improvement of LUTS and flow were consist-
ently reported [2,4,8,9] while a decrease in total serum
PSA were observed in some studies [2].
As stressed in a recent review [11], the duration of prostate
atrophy after a single BoNT/A needs to be determined.
Unfortunately, all the studies that reported on one single
intraprostatic injection of BoNT/A had a limited follow
up, during which no signs of prostate re-growth were
observed. Recently Brisinda et al [7] reported on repeated
neurotoxin injections dictated either by the lack of symp-
tomatic improvement or by symptomatic deterioration.
However duration of prostate atrophy after a single injec-
tion was again overlooked despite a follow-up of up to 30
months [7].
Quite recently, we had the opportunity to follow 21 frail
elderly patients during 6 month after 200U BoNT/A
administration. [12]. Eleven of these patients could be fol-
lowed at regular intervals in our outpatient clinic for a fur-
ther 12 months. Here we report on the changes in prostate
volume observed during the 18 month period. In addition
the evaluation of total serum PSA, lower urinary tract
symptoms and urinary flow was also investigated.
Methods
All patients gave written informed consent to participate
in this study, which was approved by the Ethics Commit-
tee of our Hospital. BoNT/A was offered as a compassion
procedure to patients on indwelling catheter and at high
risk to undergo prostate surgery due either to cardio-pul-
monary co-morbidities or to terminal disease. All patients
had been on indwelling urethral catheter for at least 3
months because of urinary retention refractory to several
attempts (at least 2 in each patient) of catheter removal
under alpha-blocker medication. At the time of enrol-
ment, all patients had stopped alpha blocker and/or 5-
alpha-reductase inhibitor medication and none of these
compounds were prescribed thereafter. Patients received
the standard evaluation for benign prostatic enlargement,
which comprised a physical examination including digital
rectal examination, prostate volume determination by
transrectal ultrasound, kidney and bladder ultrasound,
and biochemical blood tests including total prostate-spe-
cific antigen (PSA). Patients with a clinical suspicion of
harbouring prostate cancer were excluded. Exclusion crite-
ria included total PSA above 6,5 ng/ml or a suspicious dig-
ital rectal examination. In one patient with a baseline PSA
of 14,5 ng/ml, prostate cancer was excluded after a nega-
tive 12 core prostate biopsy.
From the initial group of 21 frail patients followed for 6
months and reported elsewhere (mean age of 80 years)
[12], eleven patients managed to attend all their sched-
uled visits up to 18 months post injection (1, 3, 6, 12 and
18 months). Ten patients from the initial group could not
be followed during this time length. Five remained in uri-
nary retention despite BoNT/A injection and received
additional treatments that prevented further evaluation of
BoNT/A induced prostate volume changes therefore being
excluded. Two died from underlying oncologic disease.
Three could not attend the outpatient clinic at regular
intervals due to a profound deterioration of their general
health condition.
The eleven patients, as previously reported [12], received
BoNT/A by transrectal approach under transrectal ultra-
sound guidance. Two vials of BoNT/A, (200 U of neuro-
toxin, Allergan, Irvine, CA, USA) were diluted in 8 ml of
saline. A 21-G, 20-cm long Chiba needle was placed in the
adapter of a transrectal endosonic linear transducer (Sie-
mens, Germany) and 4 ml (100 U) were injected in two
different places in each transitional zone while the diffu-
sion was controlled by ultrasound. Patients were sent
home with a Foley catheter and instructed to take cipro-
floxacin 500 mg twice a day for 7 days. One month later a
transrectal ultrasound of the prostate was repeated and
blood collected for total PSA. The Foley catheter was then
removed and all the 11 patients had spontaneous mictu-
rition. Maximum flow rate (Qmax) and post void residual
volumes (PVR) were determined. Patients maintained
spontaneous voiding up to the 18th month visit. At all vis-
its prostate volumes, total PSA, Qmax and PVR were deter-
mined. From the 3 month visit on, IPSS and QoL scores
were also evaluated (earlier IPSS determination was pre-
cluded since patients were on a catheter at baseline and
during the first month after BoNT/A). All ultrasound
examinations were performed by one single urologist (JS)BMC Urology 2009, 9:9 http://www.biomedcentral.com/1471-2490/9/9
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and the values presented refer to the total gland and not
to the transitional zone volume. Results are presented as
mean values ± standard error (SE). Mean values of each
parameter were compared by a non parametric Wilcoxon
Signed Ranks Test for paired data. A p < 0.05 was consid-
ered statistically significant.
Results
The mean age of this sub-cohort was 81,7 ± 2,6 years
(range, 61–92). Injection was well tolerated. No patient
required analgesic therapy, developed acute prostatitis,
haematuria, urethral bleeding or symptoms of botulinum
disease.
Table 1 indicates the mean values of each parameter.
Mean prostate volume was 82,2 ± 16 ml at baseline and
decreased gradually to a minimum of 49 ± 9,5 ml (p =
0,002) at 6 month, corresponding to a 40% reduction.
From this date on a slow re-growth of the glands was
observed and at 18 months mean volume was already
similar to baseline, 73 ± 16 ml, (p = 0,05). Figure 1 shows
mean prostate volume variation from baseline to the 18th
month.
Mean total serum PSA decreased from 6,7 ± 2,1 ng/ml at
baseline to 5,07 ± 1,5 ng/ml and 5,09 ± 1,4 ng/ml at 3 and
6 months respectively, corresponding to a 25% reduction.
However these changes did not reach statistical signifi-
cance (p = 0,09 and p = 0,16, respectively) At last observa-
tion mean value was 5,9 ± 1,6 ng/ml (p = 0,47). All
patients voided per urethra after catheter removal at first
month follow-up visit, and all maintained spontaneous
voiding since then. Mean Qmax was 11,3 ± 1,7 ml/sec at
1st month and maintained similar values along the 18
months of observation (Table 1). IPSS and associated QoL
scores were first evaluated when patients came to the 3
month evaluation and were 12,3 ± 1 and 3,3 ± 0,4, respec-
tively. These scores were maintained without significant
variations along the follow-up period. Mean post-void
residual volume was 73 ± 18 ml at the 1st month and also
did not show significant variations during the surveillance
period.
Discussion
The main finding coming from the analysis of this sub-
cohort was the duration of prostate atrophy after the sin-
gle injection of 200U of BoNT/A which was found to be
about 18 months. As previously stressed, the duration of
this period had never been reported. In addition we found
that the nadir of prostate volume occurred 6 months after
the neurotoxin administration.
The decrease of prostate volume uniformly described after
intraprostatic BoNT/A injections [2,10,12,13] should be
related with the widespread apoptosis that has been
detected in the gland after BoNT/A administration in rats,
dogs, and humans. Other mechanisms such as a straight
necrotic effect of the injected solution seems improbable
as cavitations were not observed in the gland tissue during
transrectal ultrasounds repeatedly carried out in this or in
other studies [2-10,12,13]. Apoptosis involves both the
epithelial and stromal components [3,8,14] and recent
observations suggest a mechanism of action involving the
impairment of the autonomic innervation [15]. As a mat-
ter of fact, Silva et al, demonstrated in the Rat that gland
apoptosis induced by intraprostatic injection of BoNT/A
was caused by the lack of a continuous sympathetic drive
[15]. BoNT/A-induced apoptosis could be prevented by
maintaining the adrenergic stimulation of the gland with
phenylephrine, an adrenergic agent, administered subcu-
taneously [15]. In spite of the rich cholinergic innervation
previously reported in the prostate [16] the impairment of
the parasympathetic innervation to the prostate atrophy
was less remarkable. Cholinergic stimulation could not
prevent BoNT/A-induced atrophy [15].
Despite the marked prostate atrophy, total serum PSA had
a very moderate decrease, not exceeding 25% at 3–6
months after BoNT/A. The changes in serum PSA after
BoNT/A injection are now at the centre of a lively debate.
One would expect that a decrease of total serum PSA
would accompany prostate tissue decrease, as usually
observed after prostatectomy. Moreover, Maria et al [2,13]
and Guercini et al [6,13], reported decreases over 50% in
serum PSA levels after prostate volume decreases. It
should, however, be stressed that other studies, like us,
did not find any decrease in total serum PSA levels regard-
less of a significant prostate atrophy. This is the case of
C h u a n g  e t  a l  [ 8 , 1 3 ]  a n d  P a r k  e t  a l  [ 1 0 , 1 3 ]  i n  w h i c h
changes of total serum PSA were non-significant. There-
fore, at this moment it is unclear why total serum PSA and
prostate size volume may not walk side by side after
BoNT/A injection. Nonetheless difficulties in matching
Mean prostate volume variation Figure 1
Mean prostate volume variation.
Mean prostate volume variation (ml)
30
40
50
60
70
80
90
baseline 1m 3m 6m 12m 18m
Time
P
r
o
s
t
a
t
e
 
v
o
l
u
m
e
 
(
m
l
)BMC Urology 2009, 9:9 http://www.biomedcentral.com/1471-2490/9/9
Page 4 of 6
(page number not for citation purposes)
prostate size and PSA variation have also been observed in
other studies. Loeb et al [17] stated that prostate volume
increases, determined by MRI, and PSA velocity do not
correlate. Despite growth rates as high as 10 cc per year,
PSA velocity was less than 0.1 ng/ml per year in most men
without prostate cancer [17]. Likewise, prostate size and
PSA decreases observed after 5α-reductase inhibitors
administration never attained similar values, the decrease
of serum PSA reaching 50% whereas prostate volume not
exceeding 25% [18].
Resumption of spontaneous voidings by the patients
included in this group should not be attributed solely to
prostate volume reduction, as a decrease in prostate tonus
was also reported after BoNT/A administration [19]. Lin et
al observed that injection of 200U BoNT/A significantly
reduced prostate urethral pressure in response to intrave-
nous adrenergic agents or electric stimulation in dog pros-
tates. Interestingly, prostate tonus, is under sympathetic
control [20], the autonomic innervation that is severely
impaired by intraprostatic BoNT/A [15].
As all patients were in indwelling catheterization, PVR,
IPSS score and Qmax were evaluated only after the suc-
cessful voiding that occurred when the urethral catheter
was removed 1 month after BoNT/A injection. This
moment to remove the catheter was chosen empirically as
such a study had never been conducted before. Neverthe-
less we took in consideration that Maria and coworkers
[2] had reported a marked reduction in prostate volume
and a discernible improvement in peak urinary flow 1
month after BoNT/A injection, suggesting that at this time
point beneficial effects of the neurotoxin were already
present. Average IPSS score varied between 10 and 12,
clearly indicating that LUTS severity remained low [21]
once the catheter was removed and spontaneous voidings
were resumed. In accordance, a low score of the associated
QoL question was found. In what concerns flow, the
mean values ranged between 10,5 and 12,3 ml/sec.
Although it might be argued that these Qmax values are
not exceptionally high, it should be remembered that at
baseline all these 11 patients were on chronic indwelling
catheterization refractory to several voiding trials. In addi-
tion, PVR remained well below 100 ml during follow up
indicating that bladder emptying was rather effective.
Intraprostatic BoNT/A injection was carried out transrec-
tally. This route was used for the first time in our initial
study [12] and it was preferred due to the experience the
authors accumulated while obtaining prostate biopsies
oriented by transrectal ultrasound. In addition, our pre-
liminary attempts revealed that this route is more repro-
ducible than the perineal one described by Maria et al [2]
and carries less risk of morbidity, namely hematuria, than
the transurethral route used by Kuo et al [4]. Transrectal
injections were well tolerated as attested in this cohort by
the lack of local or systemic side effects. The fact that gen-
eral anaesthesia was not required for prostate injection
was also a clear advantage as it allowed the procedure in
the frail elderly patients included in this study, who had a
mean age above eighty years and significant comorbidi-
ties. All the patients went home immediately after the
treatment which was performed as an office procedure.
One should realise that the study has several limitations.
The first comes from the fact that the number of patients
Table 1: Baseline characteristics and results at 1, 3, 6, 12 and 18-month evaluation. Results were compared to baseline or the first 
evaluation.
Baseline 1 month 3 months 6 months 12 months 18 months
Prostate volume 82,2 ± 16,2 68,7 ± 15,4
(p < 0,001)
59,1 ± 10,3
(p = 0,008)
49 ± 9,5
(p = 0,002)
63,8 ± 14
(p = 0,002)
73 ± 16
(p = 0,05)
t PSA 6,7 ± 2,1 6,6 ± 2,4
(p = 0,9)
5,1 ± 1,5
(p = 0,09)
5,1 ± 1,4
(p = 0,16)
5,4 ± 1,3
(p = 0,3)
5,9 ± 1,6
(p = 0,5)
PVR - 73 ± 18 82 ± 20
(p = 0,7)
55 ± 17
(p = 0,4)
64 ± 16
(p = 0,7)
58 ± 11
(p = 0,5)
Q max - 11,3 ± 1,7 12,0 ± 1,8
(p = 0,7)
12,3 ± 1,9
(p = 0,5)
11,4 ± 1,4
(p = 0,9)
10,5 ± 1,1
(p = 0,6)
IPSS - - 12,3 ± 1 10 ± 0,6
(p = 0,03)
10,8 ± 1,1
(p = 0,2)
11,3 ± 0,4
(p = 0,4)
Qol - - 3,3 ± 0,4 2,4 ± 0,2
(p = 0,12)
3 ± 0,1
(p = 0,6)
3,2 ± 0,2
(p = 0,9)BMC Urology 2009, 9:9 http://www.biomedcentral.com/1471-2490/9/9
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that could be followed during 18 months is small and rep-
resents a sub-cohort of patients that responded better to
BoNT/A injection. However the other 10 patients of the
initial cohort that could not be followed for the reasons
pointed above, all had a marked atrophy at six months
evaluation [12]. Therefore the patients reported in the
present study do not represent a special subgroup with
prostate atrophy but rather a subgroup with better clinical
outcome and/or better clinical condition to attend regular
visits. Another limitation comes from the fact that no con-
trol group exists, making a bias towards prostate atrophy
possible, albeit improbable taking in consideration the
magnitude of absolute changes. Pressure/flow studies
were not carried out, preventing therefore the correct
determination of the cause of the refractory urinary reten-
tion. However one must understand that in such a group
of frail elderly patients with large prostate glands, urinary
retention due to bladder prostatic obstruction is the likely
diagnosis. Although bladder decompensation is a well
known problem in this aged group of patients, a hypot-
onic bladder should not be the most important reason for
the refractory urinary retention present at inclusion. In
fact, these patients voided spontaneously after prostate
volume/prostate tonus reduction brought on by BoNT/A.
The third limitation is the lack of IPSS scores and QOL
scores at baseline, as patients did not void spontaneously
at inclusion. Thus, IPSS score, Qmax and PVR determined
along the study should be interpreted as an indication
that the BoNT/A effect persisted also during a long period
of time. Finally, it is unclear if the same time-response will
occur if small prostate glands are injected with BoNT/A.
Conclusion
In conclusion, our study shows that large prostate gland
atrophy that follows 200 U injection of BoNT/A is tran-
sient, volumes returning to baseline levels after 18
months. These observations may have significant impact
for the use of BoNTA in the management of BPE due to
BPH.
Intraprostatic BoNT/A injection can reduce the volume of
large prostate glands for a period of 18 months. Such a
long period of action indicates that intraprostatic BoNT/A
injections should be further investigated as a new tool for
the management of BPE due to BPH.
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